Can I swap from Mounjaro to Wegovy?
Following the recent announcement regarding the significant increase in the price list of Mounjaro (effective from 1 September 2025), many patients are considering whether Wegovy might be a suitable alternative. Below, we’ve outlined key information to help you make an informed decision in consultation with your clinician.
Which is more effective: Wegovy or Mounjaro?
The first direct head-to-head clinical trial, published in the New England Journal of Medicine in May 2025 compared Mounjaro (tirzepatide) and Wegovy (semaglutide) in 750 adults living with obesity.
Key findings:
- Weight loss: Average 20% reduction with Mounjaro vs 14% with Wegovy over 72 weeks.
- Waist circumference: 18cm average reduction with Mounjaro vs 13cm with Wegovy.
- Health markers: Both improved blood pressure, blood sugar and cholesterol
- Side effects: Similar between both groups, mainly gastrointestinal.
While this data suggests Mounjaro may deliver greater weight loss on average, it’s important to note that Wegovy remains highly effective and has additional licensing for cardiovascular protection.
Fundamentally, the drug that’s more effective depends on you and your individual health needs.
Will I need to start on the lowest dose of Wegovy?
Not necessarily. The table below outlines at which Wegovy dose you may be able to switch over to from Mounjaro. Ultimately, to ensure your body adjusts safely and reduces the risk of side effects, any switch - whether at the lowest dose or at a higher dose - is subject to clinician approval.
| Mounjaro | Wegovy |
| 2.5mg | 0.25mg |
| 5mg | 0.25mg |
| 7.5mg | 0.5mg |
| 10mg | 0.5mg |
| 12.5mg | 1mg |
| 15mg | 1mg |
| Note: Switches are subject to tolerability and will be determined based on your individual profile. Ultimately, any dose adjustment—whether starting low or higher—will be guided and approved by your clinician to ensure your body adjusts safely and to minimize the risk of side effects. As your body may take some time to adjust, you may see a temporary slow-down in the progress you’re used to, such as a brief weight-loss plateau or potential short-term weight gain. |
Here’s what we’ve seen so far:
- Mounjaro (tirzepatide) has shown greater efficacy in weight loss and glucose management, thanks to its dual-receptor approach.
-
Wegovy (semaglutide) remains a strong contender, especially for patients with high cholesterol or cardiovascular concerns, as it may offer added heart health benefits.
- Both medications have potential side effects with higher doses providing stronger results— but also possibly leading to more heightened GI (gastrointestinal) issues.
If the price change means Mounjaro is no longer a viable long-term option, our clinicians can support you with exploring your options.
Both Mounjaro and Wegovy remain excellent tools in managing obesity and related health risks. The best choice is the one that fits your health needs, lifestyle, and financial circumstances.
We’re here to help you navigate that decision with confidence and care. 🙂